 Library
of Slides and Posters |
|
|
Success
of Test and Treat in San Francisco? Reduced Time to VirologicSuppression,
Decreased Community Viral Load, and Fewer New HIV Infections, 2004
to 2009
M Das and others. CROI 2011. |
 |
Use
of Community Viral Load as Population-Based Biomarker of HIV „Ÿ
Washington, DC, 2004 . 2008
A Castel and others. CROI 2011. |
|
Disparities
in Community Viral Load among HIV Infected Persons in NYC
F Laraque and others. CROI 2011. |
|
HIV
is Associated with Clinically Confirmed Myocardial Infarction after
Adjustment for Smoking and Other Risk Factors
M Freiberg and others. CROI 2011. |
|
Contribution
of Immunodeficiency to Coronary Heart Disease: Cohort Study of HIV-infected
and HIV-uninfected Kaiser Permanente Members
D Klein and others. CROI 2011. |
|
No
Association of Myocardial Infarction with Abacavir Use: Findings of
an FDA Meta-analysis
X Ding and others. CROI 2011. |
|
Raltegravir
(RAL) Demonstrates Durable Virologic Suppression and Superior Immunologic
Response with a Favorable Metabolic Profile Through 3 Years Treatment
(Tx): 156 Week (Wk) Results from STARTMRK
J Rockstroh and others. CROI 2011. |
|
ARIEL:
24-week safety and efficacy of darunavir/ritonavir in treatment-experienced
pediatric patients aged 3 to <6 years
A Violari and others. CROI 2011. |
|
|
Pharmacokinetic
Parameters of Once-Daily TMC278 Following Administration of Efavirenz
in Healthy Volunteers
H Crauwels and others. CROI 2011. |
|
|
Lipid
profiles of TMC278 and efavirenz in treatment-naïve, HIV-1-infected
patients: pooled Week 48 data from the randomized, double-blind, Phase
III ECHO and THRIVE trials
J Arribas and others. CROI 2011. |
|
|
Neurologic
and psychiatric safety profile of TMC278 compared with efavirenz in
treatment-naïve, HIV-1-infected patients: pooled analysis from
the randomized, double-blind, Phase III ECHO and THRIVE trials at
48 weeks
A Mills and others. CROI 2011. |
|
|
Change
in Vitamin D Levels Smaller and Risk of Development of Severe Vitamin
D Deficiency Lower Among HIV-1-Infected, Treatment-naïve Adults
Receiving TMC278 Compared with Efavirenz: 48-week Results from the
Phase III ECHO Trial
D Wohl and others. CROI 2011. |
|
GS-7340
Demonstrates Greater Declines in HIV-1 RNA than Tenofovir DisoproxilFumarateDuring
14 Days of Monotherapyin HIV-1 Infected Subjects
A Diamond and others. CROI 2011. |
|
No
Association of Myocardial Infarction with ABC Use: An FDA Meta-analysis.
18th Conference on Retroviruses and Opportunistic Infections
X Ding and others. CROI 2011. |
